A Minimum 3-Year Follow-Up of Nivolumab-Plus-Ipilimumab in Japanese Patients With Advanced or Metastatic Renal Cell Carcinoma: A Final Analysis of the J-ENCORE Study - PubMed
6 hours ago
- #nivolumab
- #renal cell carcinoma
- #ipilimumab
- The J-ENCORE study evaluated nivolumab-plus-ipilimumab in Japanese patients with advanced or metastatic renal cell carcinoma.
- Real-world objective response rate was 38.4%, with 30.5% maintaining response for ≥36 months.
- Median real-world progression-free survival and second progression-free survival were 9.7 and 30.1 months, respectively.
- 60.2% of patients survived for ≥36 months.
- Treatment-related adverse events occurred in 78.5% of patients, with 43.1% being grade 3/4 and 1.1% grade 5.
- Multivariable analyses linked overall survival to age, lactate dehydrogenase, and C-reactive protein levels.
- The study supports the real-world efficacy and safety of nivolumab-plus-ipilimumab.